Trump signs order to speed review of psychedelics, including the controversial drug ibogaine

§ 01

Briefing Summary

AI-generated

NEWSAR · AI

In April 2026, President Donald Trump signed an executive order directing his administration to expedite the review process for certain psychedelic drugs, including ibogaine. Ibogaine, derived from a West African shrub, has gained attention from veterans and lawmakers for its potential to treat conditions like PTSD and opioid addiction, despite safety concerns. While these drugs remain in the most restrictive category under federal law, the administration aims to ease restrictions and encourage research into their medical applications, such as severe depression. Trump stated the order would accelerate access to potential treatments, emphasizing the potential for significant impact if the drugs prove effective. The move follows pledges from administration officials to ease access to psychedelics for medical use, reflecting bipartisan support for the issue.

Confidence 0.90Sources 2Claims 4Entities 5

§ 02

Article analysis

Model · rule-based

Framing

Public Health

Political Strategy

Tone

Measured

AI-assessed

CalmNeutralAlarmist

Factuality

0.80 / 1.00

Factual

LowHigh

Sources cited

2

Limited

FewMany

§ 03

Key claims

4 extracted

01

Ibogaine and other psychedelics remain banned under the federal government’s most restrictive category for illegal, high-risk drugs.

factualArticle

Confidence

1.00

02

President Trump directed his administration to speed up reviews of certain psychedelic drugs, including ibogaine.

factualArticle

Confidence

1.00

03

Today’s order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives.

quoteDonald Trump

Confidence

0.90

04

Ibogaine has great promise for hard-to-treat conditions such as post-traumatic stress disorder and opioid addiction.

factualVeteran organizations and psychedelic advocates

Confidence

0.70

§ 04

Full report

1 min read · 243 words

President Donald Trump holds up a signed executive order in the Oval Office of the White House, Saturday, April 18, 2026, in Washington. (AP Photo/Julia Demaree Nikhinson) 2026-04-18T14:16:09Z WASHINGTON (AP) — President Donald Trump on Saturday directed his administration to speed up reviews of certain psychedelic drugs, including Ibogaine, which recently has been embraced by combat veterans and conservative lawmakers despite having serious safety risks. Ibogaine and other psychedelics remain banned under the federal government’s most restrictive category for illegal, high-risk drugs. But the administration is taking steps to ease restrictions and spur research on using the drugs for medical purposes, including conditions like severe depression. “Today’s order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life,” Trump said as he signed an executive order on the drugs. The Republican president said his directive will help “dramatically accelerate” access to potential treatments. “If these turn out to be as good as people are saying, it’s going to have a tremendous impact,” he said. Veteran organizations and psychedelic advocates have long contended that the Ibogaine, which is made from a shrub native to West Africa, has great promise for hard-to-treat conditions such as post-traumatic stress disorder and opioid addiction. Trump’s announcement follows pledges by Health Secretary Robert F. Kennedy Jr. and other administration officials to ease access to psychedelics for medical use, an issue that has won rare bipartisan support. (

§ 05